Brown Brothers Harriman & Co. Sells 6,084 Shares of Haleon plc (NYSE:HLN)

Brown Brothers Harriman & Co. lessened its holdings in shares of Haleon plc (NYSE:HLN) by 44.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,569 shares of the company’s stock after selling 6,084 shares during the period. Brown Brothers Harriman & Co.’s holdings in Haleon were worth $72,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Thrivent Financial for Lutherans raised its position in Haleon by 69.0% during the third quarter. Thrivent Financial for Lutherans now owns 55,593 shares of the company’s stock valued at $588,000 after purchasing an additional 22,701 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Haleon by 41.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company’s stock worth $2,154,000 after buying an additional 59,719 shares in the last quarter. Aureus Asset Management LLC lifted its position in shares of Haleon by 18.3% during the 3rd quarter. Aureus Asset Management LLC now owns 14,881 shares of the company’s stock worth $157,000 after buying an additional 2,298 shares during the last quarter. Benjamin Edwards Inc. bought a new position in Haleon in the third quarter valued at about $805,000. Finally, Hilltop Holdings Inc. acquired a new position in Haleon during the third quarter worth about $133,000. 6.67% of the stock is owned by institutional investors.

Haleon Stock Down 1.1 %

Shares of HLN opened at $10.18 on Wednesday. The company has a market capitalization of $46.06 billion, a PE ratio of 29.93, a PEG ratio of 2.82 and a beta of 0.25. The stock’s 50-day moving average price is $9.98 and its two-hundred day moving average price is $9.87. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12 month low of $7.99 and a 12 month high of $10.80.

Haleon (NYSE:HLN) last announced its earnings results on Thursday, February 27th. The company reported $0.05 EPS for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. On average, analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This represents a yield of 1.6%. The ex-dividend date is Friday, April 25th. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is currently 58.97%.

Wall Street Analyst Weigh In

HLN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein lowered Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Finally, HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.